Month: September 2024

SAMPO PLC                        STOCK EXCHANGE RELEASE                  16 September 2024 at 8:35 am NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA OR SINGAPORE OR ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Sampo plc: Directed issuance of new Sampo A shares to Topdanmark shareholders in connection with the exchange offer The Board of Directors of Sampo plc (“Sampo”) has resolved on the directed issuance of new Sampo A shares to shareholders of Topdanmark A/S (“Topdanmark”) in deviation from the Sampo shareholders’ pre-emptive rights based on the final result of the recommended best and final public exchange offer made by Sampo to acquire all of the outstanding shares in Topdanmark with the exception...

SAMPO PLC                           STOCK EXCHANGE RELEASE          16 September 2024 at 8:31 amSampo plc increases its share buyback programme to EUR 475 million and extends it until 30 November 2024 Following the announcement of the final result of the exchange offer to Topdanmark shareholders, the Board of Directors of Sampo plc has resolved to increase the EUR 400 million buyback programme announced on 17 June 2024 to EUR 475 million. With the EUR 325 million allocated to the squeeze-out of the remaining Topdanmark minority shares, this brings the total amount deployed to enhance capital efficiency and EPS accretion, to EUR 800 million, as announced on 17 June 2024. In connection with the resolution to increase the total size of the buyback programme, the Board has resolved to extend the buybacks to end no later than 30 November...

OCREVUS ZUNOVO™ has the potential to expand treatment options to centres without IV infrastructure or with IV constraints, like at a doctor’s office This approval is backed by a decade of proven safety and efficacy data of Ocrevus® IV, with over 350,000 people treated globally OCREVUS ZUNOVO™ offers people with multiple sclerosis (MS) more options to access treatment based on their individual needsBasel, 16 September 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). OCREVUS ZUNOVO is the first and only twice-a-year, healthcare professional (HCP)-administered approximately...

China’s National Intellectual Property Administration has issued notification to grant patent to PolTREG Chinese patent covers intrathecal administration of PolTREG’s PTG-007 Treg cell therapy to treat multiple sclerosis Intrathecal administration demonstrated promising result in Phase I clinical trial PolTREG set to launch one Phase 2 study in each of two types of MS: relapsing-remitting (RRMS) and primary progressive (PPMS) in Q4 2024Gdańsk, Poland – 16 September 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today announces that China’s National Intellectual Property Administration, PRC (CNIPA) has issued a notification to grant a patent for the intrathecal administration of the company’s cellular therapies in patients with...

FORT WAYNE, Ind., Sept. 15, 2024 (GLOBE NEWSWIRE) — The Vera Bradley Foundation for Breast Cancer (the “Foundation”) today announced a donation of $1,601,830 to support the Vera Bradley Foundation Center for Breast Cancer Research at the Indiana University School of Medicine (“IU School of Medicine”). With this gift, the Foundation’s cumulative contributions to breast cancer research now stand at $41.7 million. The Foundation’s donation announcement was shared at its Foundation Celebration, part of the 30th annual Vera Bradley Foundation for Breast Cancer Classic. The multi-day Classic, held in Vera Bradley’s hometown of Fort Wayne, Indiana, brings hundreds of participants, sponsors, and volunteers together for a hope-filled weekend featuring women’s golf tournaments, pickleball tournaments, and a celebration event. Funding...

Mine restart funding secured and on track to deliver cashflow during H1 2025Endeavor Silver Zinc Mine Cobar NSW AustraliaEndeavor MineSYDNEY, Sept. 16, 2024 (GLOBE NEWSWIRE) — Polymetals Resources Ltd (ASX: POL) (Polymetals or the Company) is pleased to announce it has secured a Pre-payment / Loan facility to fund the Endeavor mine restart along with favourable offtake terms for delivery of zinc and silver-lead concentrates commencing during H1 2025. HIGHLIGHTSUS$20 million (~A$30 million) pre-payment/loan facility secured. Funds applied to restart of the Endeavor Mine with pre-production capital A$28m and maximum cash drawdown of A$30m1. Strategic partnership with global commodity trader Ocean Partners provides flexibility to pursue organic growth in parallel including exploration growth plan and other inorganic opportunities. Mine...

Rexel Board of Directors rejects an unsolicited preliminary proposal from QXO Rexel confirms it has received earlier this week an unsolicited, non-binding preliminary proposal from QXO regarding a potential acquisition of Rexel at an indicative price of €28.00 to €28.40 per share. Rexel’s Board of Directors has reviewed the proposal in detail and has unanimously decided not to pursue it, considering that it significantly undervalues the company and does not reflect its value creation potential through its Power Up 25 strategic plan. The Board of Directors remains highly confident in Rexel’s management to deliver the mid-term objectives presented in during the June 2024 Capital Markets Day. Indeed, Rexel’s management team has successfully demonstrated over the last few years its ability to increase the company’s underlying profitability...

Data from the IGNYTE primary analysis shows clinically meaningful activity across all subgroups, including those who had received prior anti-PD1 and anti-CTLA-4 or had primary resistance to anti-PD1 Injected and non-injected lesions responded with similar frequency, depth, duration and kinetics WOBURN, Mass., Sept. 15, 2024 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that data from the primary analysis of the IGNYTE clinical trial of RP1 combined with nivolumab were presented by Caroline Robert, M.D., Ph.D. of Gustave Roussy as a late breaking abstract during an oral session at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona. “We are excited to share the full IGNYTE primary...